Clinical trials: Myeloid Neoplasm
Acute Myeloid Leukemia
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
The goal of Phase 1 is to find the recommended dose of ziftomenib and olutasidenib in patients with relapsed/refractory AML that has a mutation in the NPM1 and IDH1 genes.
- Trial name
- NCT07411586
- Testing
- Ziftomenib, Olutasidenib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia in Remission, Lymphoma in Remission
Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft
The aim is to validate an in vitro diagnosis medical device to predict grade II to IV aGVHD after a cell graft
- Conditions
- Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts
- Trial name
- Predictor2 (NCT03887156)
- Testing
- Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
- Where
- 22 sites in Belgium, France and 1 more
- Volunteers
- 227 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-small Cell Lung Cancer(NSCLC)
the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs
Metastasis is the leading cause of death in patients with lung cancer, and circulating tumor cells(CTCs) play a key role in the process of distant metastasis.
- Trial name
- CTC-TCM-FZ (NCT02603003)
- Testing
- JinFuKang, Cisplatin, Pemetrexed
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Cancer
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation.
- Trial name
- NCT00079222
- Testing
- itraconazole, voriconazole
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study
This study evaluates whether vitamin C improves responses to epigenetic therapy with DNMTis. Half of the patients will receive vitamin C and DNMTi while the other half will receive placebo and DNMTi.
- Trial name
- EVITA-Pilot (NCT02877277)
- Testing
- Vitamin C
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Acute Myeloid Leukemia
Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation
The study will be conducted in the Department of Medical Oncology and Department of Haematology , AIIMS, Delhi. A total of 180 patients of Acute Myeloid Leukemia who are in complete remission after induction chemotherapy will be…
- Trial name
- Ara-c (NCT01615757)
- Testing
- Ara-c
- Where
- India
- Volunteers
- 180 people
- Sponsor
- All India Institute of Medical Sciences
Leukemia
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Giving chemotherapy, such as hydroxyurea, cytarabine, idarubicin, and etoposide before a donor bone marrow transplant or stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00025402
- Testing
- filgrastim, recombinant interferon alfa, busulfan
- Where
- 188 sites in Czechia, Germany and 3 more
- Volunteers
- 1,000 people
- Sponsor
- III. Medizinische Klinik Mannheim
Refractory Acute Myeloid Leukemia
Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia
This is an open label, single-arm, pilot trial to evaluate the immune effects, safety and tolerability of pembrolizumab in subjects newly diagnosed with acute myeloid leukemia (AML) who have persistent leukemia after induction…
- Trial name
- NCT03291353
- Testing
- pembrolizumab
- Where
- United States
- Sponsor
- Michael Boyiadzis
Acute Myeloid Leukemia
Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.
The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.
- Trial name
- AML_MenALLO (NCT07627568)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Freiburg
Acute Promyelocytic Leukemia
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
In this prospective randomized study for patients with newly diagnosed acute promyelocytic leukemia, patients will be randomized (1:1) into two groups which receive retinoic acid and arsenic trioxide based treatment versus…
- Trial name
- NCT01987297
- Testing
- ATRA+Arsenic, ATRA+Chemo
- Where
- China
- Volunteers
- 738 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Refractory Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia
Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML
This is a Phase I open-label dose escalation study of a single infusion of FATE-NK100 and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy (CY/FLU) in subjects with refractory or…
- Trial name
- NCT03081780
- Testing
- FATE-NK100
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myelogenous Leukemia
Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
In this study, the efficacy and safety of nilotinib 400 mg twice daily, will be compared with imatinib 400 mg twice daily in patients with a suboptimal response to imatinib for their Philadelphia chromosome-positive (Ph+) Chronic…
- Trial name
- ENEST (NCT00519090)
- Testing
- Imatinib, Nilotinib (AMN107)
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Mantle Cell Lymphoma
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
The goal of this clinical research study is to find the highest safe dose of RAD001 that can be given as a treatment for leukemia, mantle cell lymphoma, or myelofibrosis.
- Conditions
- Leukemia, Mantle Cell Lymphoma, Myelofibrosis
- Trial name
- NCT00081874
- Testing
- RAD001
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia
Patients aged ≥70 years with acute myeloid leukemia (AML) have a poorer prognosis than those aged 60 to 69 years. The poor outcome is the result of treatment-related toxicity in elderly patients, owing to comorbidities, the…
- Trial name
- NCT02844218
- Testing
- Age of patient
- Where
- France
- Volunteers
- 183 people
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Leukemia
GilteRInf 2022 Study (Gilteritinib Related Infections)
The study is observational, retrospective-prospective, multicenter "real-life" study involving 26 centers belonging to the SEIFEM group.
- Trial name
- GilteRInf (NCT05791890)
- Testing
- Gilteritinib
- Where
- Italy
- Volunteers
- 78 people
- Sponsor
- University of Rome Tor Vergata
Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
To evaluate the major molecular response (MMR) rate at 12 months of nilotinib treatment on study in patients with Philadelphia Chromosome Positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have a suboptimal…
- Trial name
- MACS0911 (NCT01043874)
- Testing
- Nilotinib
- Where
- 20 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)
Erwinaze will be administered intravenously at a dose of 25,000 IU/m2 (dose cohort 0) for 6 doses MWF over a period of 2 weeks to 9 patients (as described below and in the following schema).
- Trial name
- NCT02283190
- Testing
- Erwinase
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ashkan Emadi
Leukemia, Myeloid, Acute
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)
In this phase I extension study, the investigators seek to test the safety of both higher doses of plerixafor as well as intravenous dosing to maximize inhibition of the target, CXCR4.
- Trial name
- AML (NCT01027923)
- Testing
- Plerixafor, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Trial name
- NCT01929408
- Where
- 12 sites in United States
- Volunteers
- 703 people
- Sponsor
- Fred Hutchinson Cancer Center
Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
This phase III trial is studying how well combination chemotherapy works in treating young patients with Down syndrome and acute myeloid leukemia or myelodysplastic syndromes.
- Conditions
- Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7)
- Trial name
- NCT00369317
- Testing
- asparaginase, daunorubicin hydrochloride, cytarabine
- Where
- 97 sites in United States, Australia and 2 more
- Volunteers
- 205 people
- Sponsor
- Children's Oncology Group